A test method for assessment of spill and leakage from drug preparation systems

Annals of Occupational Hygiene

Volumn 49, Issue 8, 2005, Pages 711-718

  Nygren, Olle ^a   Gustavsson, Bengt ^b   Eriksson, Robert ^b  

^a NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug leakage; Preparation and administration systems; Technetium; Test method

Indexed keywords

DRUG PRODUCTS; HEALTH RISKS; LEAKAGE (FLUID); OCCUPATIONAL DISEASES; TECHNETIUM; DISEASES; TESTING;

DRUG LEAKAGE; PREPARATION AND ADMINISTRATION SYSTEMS; TEST METHODS;

HAZARDOUS MATERIALS SPILLS;

ANTINEOPLASTIC AGENT; TECHNETIUM 99M;

ANALYTIC METHOD; ARTICLE; DRUG INDUSTRY; FILTER; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; SPIKE; SPILLAGE; VALIDATION PROCESS; WORK ENVIRONMENT;

ACCIDENTS, OCCUPATIONAL; ANTINEOPLASTIC AGENTS; DRUG PACKAGING; ENVIRONMENTAL MONITORING; HUMANS; OCCUPATIONAL EXPOSURE; RADIOPHARMACEUTICALS; TECHNETIUM;

ADVERSE HEALTH EFFECTS; BIOLOGICAL SAFETY; DRUG LEAKAGE; DRUG PREPARATION; OCCUPATIONAL EXPOSURE; PREPARATION AND ADMINISTRATION SYSTEMS; STEP BY STEP PROCEDURE; TEST METHOD;

EID: 27944461876     PISSN: 00034878     EISSN: 14753162     Source Type: Journal    
DOI: 10.1093/annhyg/mei039     Document Type: Article

References (16)

1. AFS Ordinance (1999) AFS 1999:11 Cytostatika och andra läkemedel med bestående toxisk effekt [Cytostatics and other drugs with permanent toxic effect.] (in Swedish). Arbetarskyddsstyrelsens Författningssamling, Publikationsservice, Stockholm.
2. 99mTc in hospitals. Final report from SSI project P 154-80.] (in Swedish). SSI rapport 83-18, Statens Strålskyddsinstitut, Stockholm.
3. Bos RP, Sessink PJM. (1997) Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health; 12: 43-58.
4. Drug standard (1999) Läkemedelsstandard 99 (in Swedish). Svenska farmakopékommitténs Sekretariat, Swedish Medical Product Agency, Uppsala, Sweden.
5. Ensslin AS, Pethran A, Schierl R et al. (1994) Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health; 65: 339-42.
6. Hedmer M, Jönsson BA, Nygren O. (2004) Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. J Environ Monit; 6: 979-84.
7. ICRP. (2002) Recommended maximum radiation doses. (Stockholm, Sweden: International Commission on Radiological Protection). Available on http://www.icrp.org.
8. Kromhout H, Hoek F, Uitterhoeve R et al. (2000) Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg; 44: 551-60.
9. Nygren O, Vaughan GT, Florence MT et al. (1990) Determination of platinum in blood by adsorptive voltammetry. Anal Chem; 62: 1637-40.
10. Nygren O, Lundgren C. (1997) Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health; 70: 209-14.
11. Nygren O. (2002) New approaches for assessment of occupational exposure to metals using on-site measurements. J Environ Monit; 4: 623-7.
12. Nygren O, Gustavsson B, Ström L et al. (2002) Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit; 4: 739-42.
13. Nygren O, Aspman O. (2004) Validation and application of wipe sampling and portable XRF analysis as an on-site screening method for assessment of deposited aerosols on workplaces. Aust J Chem; 37: 1021-8.
14. Sessink PJM, Anzion RB, Van den Broek PHH et al. (1992) Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci; 14: 16-22.
15. Sessink PJM, Kroese ED, van Kranen HJ et al. (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health; 67: 317-23.
16. Sessink PJM, Wittenhorst BCJ, Anzion RBM et al. (1997) Exposure of pharmacy technicians to antineoplastic agents: re-evaluation after additional protective measures. Arch Environ Health; 52: 240-4.